

## Supplemental Document

**Table S1. Effect of exogenous C0C2 on steady-state parameters in skinned myocardium**

Steady-state parameters in skinned myocardium		
	WT (n=4)	cMyBPC <sup>-/-</sup> (n=4)
F <sub>min</sub> (mN/mm <sup>2</sup> ) baseline	1.01±0.16	0.85±0.13
F <sub>min</sub> (mN/mm <sup>2</sup> ) +C0C2	1.17±0.16	1.70±0.34*
F <sub>max</sub> (mN/mm <sup>2</sup> ) baseline	16.07±1.36	15.28±3.01
F <sub>max</sub> (mN/mm <sup>2</sup> ) +C0C2	16.71±1.63	15.60±2.86


Quantification of Ca<sup>2+</sup>-independent force (F<sub>min</sub>) in pCa 9.0 and maximum Ca<sup>2+</sup> activated force (F<sub>max</sub>) in pCa 4.5, before and after a 10 minute 1.0µM C0C2 incubation. F<sub>min</sub>: Ca<sup>2+</sup>-independent force measured at pCa 9.0; F<sub>max</sub>: Ca<sup>2+</sup>-activated maximal force measured at pCa 4.5. n=number of hearts per group. Values are expressed as mean ± S.E.M; \* indicates significant difference (p<0.05) by paired t-test when comparing respective pre- and post- C0C2 incubation.

**Table S2. Effect of exogenous C0C2 on stretch-activation parameters in skinned myocardium**

Dynamic stretch-activation parameters in skinned myocardium		
	WT (n=4)	cMyBPC <sup>-/-</sup> (n=4)
$k_{\text{rel}}$ (s <sup>-1</sup> ) baseline	481.16±68.95	947.72±41.85
$k_{\text{rel}}$ (s <sup>-1</sup> ) +C0C2	459.12±69.74	733.64±50.37*
$\Delta k_{\text{rel}}$ (%)	-4.84±4.47	-22.44±5.14
$k_{\text{df}}$ (s <sup>-1</sup> ) baseline	3.35±0.53	7.07±0.28
$k_{\text{df}}$ (s <sup>-1</sup> ) +C0C2	3.21±0.46	4.60±0.39*
$\Delta k_{\text{df}}$ (%)	-3.89±3.81	-33.90±7.95#

Stretch-activation parameters measured before and after a 10 minute 1.0μM C0C2 incubation at pCa 6.1.  $k_{\text{rel}}$ : rate of XB detachment;  $k_{\text{df}}$ : rate of XB recruitment. n=number of hearts per group. Values are expressed as mean ± S.E.M; \* indicates significant difference ( $p<0.05$ ) by paired t-test when comparing respective pre- and post- C0C2 incubation. # indicates significant difference in % change of stretch-activation rate constant between WT and cMyBPC<sup>-/-</sup> groups.

**Figure S1**



**Figure S1: Myofilament Ca<sup>2+</sup> sensitivity (pCa<sub>50</sub>) in cardiac preparations from AAV-9 injected groups.** Force-pCa relationships were constructed by plotting normalized forces generated at a range of pCa to assess pCa<sub>50</sub> in WT hearts and cMyBPC<sup>-/-</sup> hearts injected with AAV9-GFP, or -FL, or -C0C2 cMyBPC. No significant differences in pCa<sub>50</sub> were observed between the groups. 12 myocardial preparations from 4 hearts were used for all the groups.

**Figure S2:**

```
1 atgccggagc cagggaaagaa accagtgtca gccttcaaca agaagccaag  
51 gtcagcggag gtgaccgctg gcagtgtgc cgtgttcgag gctgAgacgg  
101 agcggtcagg cgtgaaggtg cggtggcagc gggatggcag cgacatcacc  
151 gccaatgaca agtatggttt ggcagcagag ggcaagcgGc acacactgac  
201 agtgccggat gcgagccctg atgaccaggg ttccctacgctg gtcattgcag  
251 gctcctcaaa ggtcaagttt gacctcaagg tcacagagcc agcccctcca  
301 gagaaggcag aatctgaagt tgctccagga gcccccaaag aagtccctgc  
351 tccagccact gagttggaag aaagtgtctc aagtcctgaa gggtcagtct  
401 cggttaaccca ggtatggctca gctgcagagc atcagggagc ccctgatgac  
451 cctattggcc tctttctgat gcgaccacag gatggtgagg tgaccgtggg  
501 cggcagcatt gtcttctcag cccgagttgc tggggccagc ctccctgaaac  
551 cgcctgtggt caagtggttc aagggaagt gggtgacact gagcagcaaa  
601 gtgggccagc acTtgcagct gcatgacagc tatgacagag ccagcaaggt  
651 ctacttgttt gagttgcaca tcacagatgc tcagaccact tctgctgggg  
701 gctaccgctg tgaggtgtct accaaggaca aatttgacag ctgtaActtc  
751 aacctcactg tccatgagggc cattgggtct ggagacactgg acctcagatc
```

801 agcttccga cgcacgAGCc tGgcgggagc AggTcgaga accAGtgaca  
851 gccatgaaga tgctggact ctggacttta gttccctgct gaagaagaga  
901 gacAGTttcc ggagggactc aaagctggag gcacacctg aagaagacgt  
951 gtggagatc ctgagacagg caccgccgtc agaatatgag cgcatcgccct  
1001 tccagcacgg agtcacagac ctgcaggca tgctgaagag gctcaagggc  
1051 atgaagcagg atgaaaagaa gagcacagcc ttgcagaaga agctggagcc  
1101 tgcctaccag gtaaacaagg gccacaagat tcggcttact gtggaactgg  
1151 ctgatccgga cgccgaagtc aagtggcttta agaatggaca ggagatccag  
1201 atgagtggca gcaagtacat ctgcagtc gtcggtgcca agcgcaccct  
1251 gaccatcagc cagtgcac tggctgacga cgcagcctac cagtgtgtgg  
1301 tggggggcga gaagtgcagc acggagctct ttgtcaaaga gccccggtg  
1351 ctgatcaactc ggtccctgga agaccagctg gtgatggtggt gtcagcgggt  
1401 ggagtttgag tgtgaggtct cagaagaagg ggcccaagtc aaatggctga  
1451 aggatggggt tgaGctgaca cgtgaggaga cttcaaaata ccgggtcaag  
1501 aaagatgggc ggaaacacca cttgatcatc aatgaagcaa ccctggagga  
1551 tgcaggacac tatgcagtc acacaagtgg aggccagtca ctggctgagc  
1601 tcattgtgca agagaagaag ttggaggtat accaaagcat cgccggacctg


1651 gcagtggag ccaaggacca ggctgtgtt aagtgtgagg tttcagatga  
1701 gaatgtacgc ggcgtgtggc tgaagaatgg gaaggaactg gtgcctgaca  
1751 accgcataaa ggtgtcccat ataggccggg tccacaaact gaccattgac  
1801 gatgtcacac ctgctgatga ggctgactac agctttgtcc ctgaagggtt  
1851 tgcctgcaac ctgtctgcc a gctccactt catggaggtc aagattgact  
1901 ttgtgcctag gcaggaacct cccaagatcc acttggattg tcccggcagc  
1951 acaccagaca ccattgtggt tggtgctggg aacaagttac gcctggatgt  
2001 ccctatttct ggagaccctg ctcccactgt ggtctggcag aagactgtaa  
2051 cacagggaa gaaggcctca actgggccac accctgatgc cccagaagat  
2101 gctggtgctg atgaggagtg ggtgtttgat aagaagctgt tgtgtgagac  
2151 tgagggccgg gtccgggtgg agaccaccaa agaccgcagc gtctttacag  
2201 tcgaaggggc agAgaaggaa gatgaagggtg tctacacagt cacagtaaag  
2251 aaccccggtgg gcgaggacca ggtcaacctc acagtcaagg tcatcgatgt  
2301 cccagatgct cctgcggccc ctaagatcag caacgtggc gaggactcct  
2351 gcactgtgca gtgggaaccg cctgcctatg atggcgggca gccggtcctg  
2401 ggatacatcc tggagcgcaa gaagaaaaag agctacaggt ggatgaggct  
2451 caactttgat ctgctgcggg agctgagcca cgagggcgagg cgcatgatcg

2501 agggtgttagc ctatgagatg cgagtctacg cagtcaatgc cgtggaaatg  
2551 tccaggccccca gccctgcctc tcagcccttc atgcctattg ggccccctgg  
2601 cgaaccaacc cacttggctg tggaggatgt gtcagacacc actgtctcac  
2651 tcaagtggcg gcccccaagag cgcggtggggg ccgggtggcct ggacggatac  
2701 agcgtggagt actgccagga gggatgctcc gagtgacac acgtctgca  
2751 ggggctgaca gagcgcacat cgatgctggt gaaggaccta cccactgggg  
2801 cacggctgct gttccgagta cgggcacaca atgtggcagg tcctggaggc  
2851 cctatcgtca ccaaggagcc tgtgacagtg caggagatac tgcaacgacc  
2901 acggctccaa ctgcccagac acctgcgcacca gaccatccag aagaaagttg  
2951 gggagcctgt gaacctcctc atccctttcc agggcaaacc ccggcctcag  
3001 gtgacctgga ccaaagaggg gcagccccctg gcaggtgagg aggtgagcat  
3051 ccggAACAGC CCCACAGACA CGATCTTGTt CATCCGAGCT GCCCGCCGCA  
3101 cccactcggg cacctaccag gtgacagttc gcattgagaa catggaggac  
3151 aaggcaacgc tgatcctgca gattgtggac aagccaagtc ctccccagga  
3201 tatccggatc gttgagactt ggggtttcaa tgtggctctg gagtggaaagc  
3251 caccccaaga tcatggcaat acagagatct ggggttatac tgtacagaaa  
3301 gctgacaaga agaccatgga gtggttcacg gttttggaaac actaccgacg

3351 cactcactgt gtggtatcat agcttatcat tggcaatggc tactacttcc  
3401 gggtcttcag ccataacatg gtgggttcca gtgacaaagc tgccgccacc  
3451 aaggagccag tctttattcc aagaccaggc atcacatatg agccacccaa  
3501 atacaaggcc ctggacttct ctgaggcccc aagcttcacc cagcccttgg  
3551 caaatcgctc catcattgca ggctataatg ccatcctctg ctgtgctgtc  
3601 cgaggtagtc ctaagccaa gatttcctgg ttcaagaatg gcctggatct  
3651 gggagaagat gctcgcttcc gcatgttctg caagcaggga gtattgaccc  
3701 tggagatcag gaaaccctgc ccctatgatg gtggtgtcta tgtctgcagg  
3751 gccaccaact tgcagggcga ggcacagtgt gagtgccgcc tggaggtgcg  
3801 agttcctcag tga

**Figure S2: cMyBPC cDNA sequence.** Murine FL cMyBPC cDNA Sequence used in AAV9-vectored constructs. The N-terminal C0C2 sequence is highlighted in grey.


**Figure S3**




**Figure S3: Recombinant C0C2 purification.** **(A)** Representative size-exclusion chromatography (SEC) profile of recombinant C0C2 purification. A single major peak is found at the elution volume corresponding to monomeric C0C2 (~49kD). **(B)** Representative Coomassie staining image of SDS-page gel with molecular weight ladder (lane 1), total protein lysate before purification (lane 2), and protein sample from peak fraction collected from SEC (lane 4). Lane 3 was left blank to allow for SEC sample to run unimpeded. The higher concentration of lane 3 loading confirms the absence of major trace contaminants after purification.

**Figure S4**

A



B



**Figure S4: Quantification of relative HSC70 expression.** (A) Representative Western blot showing the expression of HSC70 and GAPDH in WT (lane 1), AAV9-GFP treated cMyBPC<sup>-/-</sup> (lane 2), AAV9-FL treated cMyBPC<sup>-/-</sup> hearts (lane 3), and AAV9-C0C2 treated cMyBPC<sup>-/-</sup> hearts (lane 4). (B) Quantification of HSC70:GAPDH in WT, AAV9-GFP treated cMyBPC<sup>-/-</sup>, AAV9-FL treated cMyBPC<sup>-/-</sup> hearts, and AAV9-C0C2 treated cMyBPC<sup>-/-</sup> hearts. n=8 per group.